A Phase II, Open-label, Single-arm Study of NEoadjuvant Zanzalintinib (XL092) Plus NivoLumab in Patients with LOcally Advanced And/or InopeRable ClEar Cell Renal Cell Carcinoma with or Without Non-measurable Metastasis (EXPLORE-RCC)
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Zanzalintinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms EXPLORE-RCC
- 04 Feb 2025 New trial record